Known targets — ChEMBL curated mechanism
BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12
The experimentally established mechanism targets of Ammonia Solution, Strong. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.94 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL61101 | 1.00 | TSHR (0.94) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| Ammonia Solution, Strong SCHEMBL4472414 | 1.00 | TSHR (0.94) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| Ammonia Solution, Strong SCHEMBL11066280 | 1.00 | TSHR (0.94) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| Ammonia Solution, Strong SCHEMBL11068109 | 0.97 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| Ammonia Solution, Strong SCHEMBL11068107 | 0.97 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| Ammonia Solution, Strong SCHEMBL11062657 | 0.97 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| Ammonia Solution, Strong SCHEMBL11062655 | 0.97 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| Ammonia Solution, Strong SCHEMBL11066264 | 0.97 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| SCHEMBL597672 | 0.97 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| SCHEMBL3409457 | 0.97 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101796033-A | As CB 1The piperazine of the replacement of antagonist | SCHERING CORP | 2010-08-04 | — | — | CN | disclosed |
| CN-101243045-A | New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | CN | disclosed |
| CN-101243077-A | Novel 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | CN | disclosed |
| CN-101228123-A | Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia | ASTRAZENECA AB (SE) | 2008-07-23 | — | — | CN | disclosed |
| CN-101223163-A | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2008-07-16 | — | — | CN | disclosed |
| CN-101068546-A | Pharmaceutical composition, process for producing the same, and method for stabilizing dihydropyridine compound in pharmaceutical composition | EISAI R&D MAN CO LTD (JP) | 2007-11-07 | — | — | CN | disclosed |
| EP-1400517-B1 | process for the preparation of 2-Phenyl-1H-benzimidazole-5-sulfonic acid from 3,4-Diaminobenzenesulfonacid | SALTIGO GMBH (DE) | 2007-01-10 | — | — | EP | disclosed |
| CN-1665783-A | Diphenylazetidinone derivatives for the treatment of disorders of lipid metabolism | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | CN | disclosed |
| EP-1400517-A2 | 2-Phenyl-1H-benzimidazole-5-sulfonic acid prepared from 3,4-Diaminobenzenesulfonacid and its use in the cosmetic compositions | Bayer Chemicals AG (DE) | 2004-03-24 | — | — | EP | disclosed |